Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carbon C 14 selumetinib

A radioconjugate containing the orally available selumetinib, an inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) types 1 and 2, labeled with the radioisotope carbon C 14. Upon oral administration, selumetinib selectively inhibits MEK1/2, which prevents the activation of MEK1/2 dependent effector proteins and transcription factors. This leads to an inhibition of cellular proliferation in MEK1/2-overexpressing tumor cells. MEK 1 and 2 are dual-specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in various cancer cells. Selumetinib radiolabeled with carbon C-14 may be used as a radiotracer for pharmacokinetic studies of this agent, including its absorption, distribution, metabolism and excretion (ADME).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Abbreviation:[14C] selumetinib
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search